Anuh Pharma Ltd. (ANUHPHR) — Tipsheet

Anuh Pharma's FY26 revenue rose 16.6% but profit fell 13.3%

Tipsheet Editorial — Thu, 21 May 2026 12:53:39 GMT

The divergence between topline growth and bottomline decline is the standout signal in an otherwise routine annual results filing. Dividend recommended at ₹1.50 per share.

What’s new

FY26 revenue up 16.6% but PAT down 13.3% vs prior year.
Board recommended ₹1.50/share dividend for FY26.
Routine reappointments of directors, auditors, and promoter reclassification approved.

Why it matters

Revenue growth without profit expansion typically points to margin compression or higher costs. For a pharma company, this divergence merits attention as it may signal input cost pressures or pricing weakness. The dividend hike could be an attempt to offset investor disappointment from the profit decline.

What we’re watching

Whether margin trends improve in Q1FY27.
Any management commentary on cost drivers or growth drivers.
The outcome of promoter reclassification and its governance implications.

The full read

Anuh Pharma reported a 16.6% rise in annual revenue to an undisclosed amount, but profit after tax dropped 13.3% for the year ended March 2026. That is the headline number that jumps out from an otherwise standard audited results filing. The board also recommended a dividend of ₹1.50 per share, a modest increase from prior levels, and approved routine items such as director reappointments and the appointment of an internal auditor and cost auditor. The divergence between revenue and profit is the real story here. It suggests the company is growing but not efficiently, either because input costs are rising or pricing power is weakening. For investors, the dividend offers some return but does not address the underlying margin question. The next quarterly numbers will be the first test of whether this is a one-off or a trend.

Primary source: BSE · NSE

Anuh Pharma revenue up 16%, but profit slips 13% in FY26

Tipsheet Editorial — Wed, 20 May 2026 23:56:39 GMT

Top-line growth couldn't protect margins: PAT fell to ₹41.05 cr despite a ₹771.66 cr top line.

What’s new

Revenue grew 16.6% to ₹771.66 cr in FY26.
Profit after tax dropped 13.3% to ₹41.05 cr.
Board recommended a ₹1.50/share dividend, flat YoY.

Why it matters

This divergence between top-line growth and bottom-line pressure signals margin compression. With revenue up but profit down, the company's cost structure or pricing power is under strain. Investors should look past the growth headline to earnings quality.

What we’re watching

Margin trajectory in Q1 FY27 results.
Management's commentary on cost pressures or one-off items.
Any guidance on volume vs pricing mix.

The full read

Anuh Pharma reported a 16.6% revenue jump to ₹771.66 cr for FY26, but profit after tax fell 13.3% to ₹41.05 cr — a rare divergence that shifts the narrative from growth to margin health. The ₹1.50/share dividend recommendation matches the prior year. Other board items — reappointments, auditor appointments, promoter reclassification — are procedural. The key takeaway is that rising top line didn't convert to profit, raising questions on input costs or pricing. The next quarter will show whether this is a blip or a trend.

Primary source: BSE · NSE

Anuh Pharma's profit slipped 13% even as revenue rose 17% in FY26

Tipsheet Editorial — Wed, 20 May 2026 22:52:42 GMT

The ₹771 cr pharma company saw a margin squeeze; board recommends ₹1.50 dividend.

What’s new

Revenue grew 16.6% to ₹771.66 crore for FY26.
Net profit fell 13.3% to ₹41.05 crore, a margin squeeze.
Board recommended a dividend of ₹1.50 per share.

Why it matters

Anuh Pharma's top line continues to expand, but the bottom line tells a different story. The 13% profit decline amid 17% revenue growth points to margin compression — likely from input costs or competitive pricing. The dividend recommendation signals the board's confidence, but the earnings quality warrants closer scrutiny.

What we’re watching

Whether margin recovery is in sight for the current year.
Any management commentary on the revenue-profit divergence.
Impact of promoter reclassification on governance.

The full read

Anuh Pharma's FY26 results show a classic divergence: revenue up, profit down. The company reported sales of ₹771.66 crore, a 16.6% gain, but net profit slipped 13.3% to ₹41.05 crore. The board recommended a ₹1.50 dividend, a routine gesture. The rest of the board meeting covered standard housekeeping: reappointments, auditor appointments, and a previously flagged promoter reclassification. The results are audited and periodic, but the gap between revenue and profit growth is the one fresh data point investors have to work with. It raises questions about cost management or pricing power in the pharma business. Without a concall transcript accompanying this filing, the next test will be whether management addresses the margin compression in subsequent disclosures.

Primary source: BSE · NSE

Anuh Pharma's profit slipped 13% despite 16.6% revenue growth

Tipsheet Editorial — Wed, 20 May 2026 21:58:36 GMT

Revenue rose to ₹771.66 cr but PAT fell to ₹41.05 cr; board recommends ₹1.50/sh dividend.

What’s new

Annual profit fell 13.3% to ₹41.05 cr despite 16.6% revenue growth to ₹771.66 cr.
Board recommends ₹1.50 per share dividend for FY26.
Audited results for quarter and year ended March 31, 2026 approved.

Why it matters

The gap between double-digit revenue growth and a profit decline points to margin compression. The next test is whether this is a one-off quarter or the start of a trend.

What we’re watching

Whether FY27 guidance or commentary addresses margin recovery.
Any specific cost head that caused the dip — raw materials or SG&A.
Q4 alone numbers if disclosed separately.

The full read

Anuh Pharma's FY26 audited results show revenue climbing 16.6% to ₹771.66 crore, while profit after tax dropped 13.3% to ₹41.05 crore. That divergence — growth without earnings follow-through — is the story. The board recommended a ₹1.50 per share dividend, a routine payout. The filing is a scheduled outcome, but the financial pattern is not: top-line momentum meeting bottom-line headwinds. What matters now is whether margins stabilise or erode further.

Primary source: BSE · NSE